ERIC ROHREN to Retrospective Studies
This is a "connection" page, showing publications ERIC ROHREN has written about Retrospective Studies.
Connection Strength
0.154
-
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12.
Score: 0.035
-
Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality. J Nucl Med Technol. 2011 Jun; 39(2):83-90.
Score: 0.026
-
F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review. Clin Nucl Med. 2011 Feb; 36(2):96-100.
Score: 0.026
-
Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978.
Score: 0.010
-
Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016 Jan; 43(1):8-20.
Score: 0.009
-
(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013 Dec; 40(12):1809-16.
Score: 0.008
-
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
Score: 0.007
-
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94.
Score: 0.006
-
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
Score: 0.006
-
Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44.
Score: 0.006
-
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11.
Score: 0.006
-
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009 Mar; 50(3):340-7.
Score: 0.006
-
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009 Feb; 50(2):231-8.
Score: 0.006